Development of WHO guidelines on generalized cost-effectiveness analysis

Health Economics

Volumn 9, Issue 3, 2000, Pages 235-251

  Murray, Christopher J L ^a   Evans, David B ^a   Acharya, Arnab ^b   Baltussen, Rob M P M ^c  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b HARVARD CENTER FOR POPULATION AND DEVELOPMENT STUDIES   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cost effectiveness analysis; Guidelines; Resource allocation

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE DELIVERY; PRIORITY JOURNAL; RESOURCE ALLOCATION; WORLD HEALTH ORGANIZATION;

COST-BENEFIT ANALYSIS; DECISION MAKING; GUIDELINES; HEALTH CARE RATIONING; HUMANS; MODELS, ECONOMETRIC; WORLD HEALTH ORGANIZATION;

EID: 0034066723     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O     Document Type: Article

References (153)

1. al Umran, K. and Yaseen, H. Cost-effectiveness of surfactant replacement therapy in a developing country. Journal of Tropical Pediatrics 1997; 43: 167-169.
2. Avants, S.K., Margolin, A., Sindelar, J.L. et al. Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost. American Journal of Psychiatry 1999; 156: 27-33.
3. Mauskopf, J., Lacey, L., Kempel, A. et al. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates. American Journal of Management Care 1998; 4: 1004-1012.
4. Morris, S., Gray, A., Noone, A. et al. The costs and effectiveness of surveillance of communicable disease: a case study of HIV and AIDS in England and Wales. Journal of Public Health Medicine 1996; 18: 415-422.
5. Platis, H. and Liaropoulos, L. Comparative cost analysis of two different medical interventions: educational implications. Studies in Health Technology and Information 1998; 51: 50-64.
6. Porta, M., Rizzitiello, A., Tomalino, M. et al. Comparison of the cost-effectiveness of three approaches to screening for and treating sight-threatening diabetic retinopathy. Diabetes Metabolism 1999; 25: 44-53.
7. Streitz J.M.J., Ellis, F.H.J., Tilden, R.L. et al. Endoscopie surveillance of Barren's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. American Journal of Gastroenterology 1998; 93: 911-915.
8. Szucs, T.D. Pharmaco-economic aspects of lipid-lowering therapy: is it worth the price? European Heart Journal 1998; 19(Suppl M): 22-28.
9. Willke, R.J., Glick, H.A., Polsky, D. et al. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Economics 1998; 7: 481-493.
10. Elixhauser, A., Luce, B.R., Taylor, W.R. et al. Health care CBA/CEA: an update on the growth and composition of the literature. Medical Care 1993; 31(Suppl): 1-149.
11. Elixhauser, A., Halpern, M., Schmier, J. et al. Health care CBA and CEA from 1991 to 1996: an updated bibliography. Medical Care 1998; 36(Suppl): 1-147.
12. Drummond, M., Torrance, G. and Mason J. Cost-effectiveness league tables: more harm than good? Social Science Medicine 1993; 37: 33-40.
13. Hoerger, T.J., Bala, M.V., Rowland, C. et al. Cost effectiveness of pramipexole in Parkinson's disease in the US. PharmacoEconomics 1998; 14: 541-557.
14. Mason, J., Drummond, M. and Torrance, G. Some guidelines on the use of cost effectiveness league tables. British Medical Journal 1993; 306: 570-572.
15. Schulman, K.A., Lynn, L.A., Click, H.A. et al. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Annals of Internal Medicine 1991; 114: 798-802.
16. Torrance, G.W. and Zipursky, A. Cost-effectiveness of antepartum prevention of Rh immunization. Clinical Perinatology 1984; 11: 267-281.
17. Williams, A. Economics of coronary artery bypass grafting. British Medical Journal, Clinical Research Edition 1985; 291: 326-329.
18. Karlsson, G. and Johannesson, M. Cost-effectiveness analysis and capital costs. Social Science Medicine 1998; 46: 1183-1191.
19. Ackerman, S.J., Sullivan, E.M., Beusterien, K.M. et al. Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS. PharmacoEconomics 1999; 15: 179-195.
20. Hay, J.W., Yu, W.M. and Ashraf T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. PharmacoEconomics 1999; 15: 47-74.
21. Patel, S.T., Haser, P.B., Bush, H.L.J. et al. The cost-effectiveness of endovascular repair versus open surgical repair of abdominal aortic aneurysms: a decision analysis model. Journal of Vascular Surgery 1999; 29: 958-972.
22. Johannesson, M. and Weinstein, M.C. On the decision rules of cost-effectiveness analysis. Journal of Health Economics 1993; 12: 459-467.
23. Birch, S. and Gafni, A. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? Journal of Health Economics 1992; 11: 279-296.
24. Birch, S. and Gafni, A. Changing the problem to fit the solution: Johannesson and Weinstein's (mis)application of economics to real world problems. Journal of Health Economics 1993; 12: 469-476.
25. Karlsson, G. and Johannesson, M. The decision rules of cost-effectiveness analysis. PharmacoEconomics 1996; 9: 113-120.
26. Nord, E. Health status index models for use in resource allocation decisions. A critical review in the light of observed preferences for social choice. International Journal of Technology Assessment in Health Care 1996; 12: 31-44.
27. Ubel, P.A., DeKay, M.L., Baron, J. et al. Cost-effectiveness analysis in a setting of budget constraints - is it equitable? New England Journal of Medicine 1996; 334: 1174-1177.
28. Weinstein, M.C. Principles of cost-effective resource allocation in health care organizations. International Journal of Technology Assessment in Health Care 1990; 6: 93-103.
29. Weinstein, M.C. and Stason, W.B. Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine 1977; 296: 716-721.
30. Birch, S. and Donaldson, C. Cost-benefit analysis: dealing with the problems of indivisible projects and fixed budgets. Health Policy 1987; 7: 61-72.
31. Birch, S., Leake, J.L. and Lewis, D.W. Economic issues in the development and use of practice guidelines: an application to resource allocation in dentistry. Community Dental Health 1996; 13: 70-75.
32. Murray, C.J., Kreuser, J. and Whang, W. Cost-effectiveness analysis and policy choices: investing in health systems. Bulletin of the World Health Organization 1994; 72: 663-674.
33. Chen, M.M. and Bush, J.W. Maximizing health system output with political and administrative constraints using mathematical programming. Inquiry 1976; XIII: 215-227.
34. Stinnett, A.A. and Paltiel, A.D. Mathematical programming for the efficient allocation of health care resources. Journal of Health Economics 1996; 15: 641-653.
35. Oregon Health Services Commission. Oregon Medicaid priority setting project. Oregon State Government, Portland, OR, 1991.
36. Blumstein, J.F. The Oregon experiment: the role of cost-benefit analysis in the allocation of Medicaid funds. Social Science Medicine 1997; 45: 545-554.
37. Brown, L.D. The national politics of Oregon's rationing plan. Health Affiliation Millwood 1991; 10: 28-51.
38. Dixon, J. and Welch, H.G. Priority setting: lessons from Oregon. Lancet 1991; 337: 891-894.
39. Fox, D.M. and Leichter, H.M. Rationing care in Oregon: the new accountability. Health Affiliation Millwood 1991; 10: 7-27.
40. Kitzhaber, J.A. Prioritising health services in an era of limits: the Oregon experience. British Medical Journal 1993; 307: 373-377.
41. Jamison, D.T., Mosley, W.H., Measham, A.R. and Bobadilla J.L. Disease control priorities in developing countries. Set. New York: Oxford University Press, 1993.
42. Tengs, T.O., Adams, M.E., Pliskin, J.S. et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995; 15: 369-390.
43. Tengs, T.O., Meyer, G., Siegel, J.E. et al. Oregon's Medicaid ranking and cost-effectiveness: is there any relationship? Medical Decision Making 1996; 16: 99-107.
44. Bobadilla, J.L. Searching for essential health services in low- and middle-income countries: a review of recent studies on health priorities. Washington DC: Human Development Department, World Bank, 1996.
45. Bobadilla, J.L., Cowley, P., Musgrove, P. et al. Design, content and financing of an essential national package of health services. Bulletin of the World Health Organization 1994; 72: 653-662.
46. Nord, E. An alternative to QALYs: the saved young life equivalent (SAVE). British Medical Journal 1992; 305: 875-877.
47. Nord, E., Richardson, J. and Macarounas, K.K. Social evaluation of health care versus personal evaluation of health states. Evidence on the validity of four health-state scaling instruments using Norwegian and Australian surveys. International Journal of Technology Assessment in Health Care 1993; 9: 463-478.
48. Nord, E. The relevance of health state after treatment in prioritising between different patients. Journal of Medical Ethics 1993; 19: 37-42.
49. Nord, E., Richardson, J., Street, A. et al. Maximizing health benefits vs egalitarianism: an Australian survey of health issues. Social Science Medicine 1995; 41: 1429-1437.
50. Black, D., Morris, J.N., Smith, C. et al. Better benefits for health: plan to implement the central recommendation of the Acheson report. British Medical Journal 1999; 318: 724-727.
51. Jarman, B. and Bosanquet, N. Primary health care in London - changes since the Acheson report. British Medical Journal 1992; 305: 1130-1133.
52. Williams, A. Intergenerational equity: an exploration of the 'fair innings' argument. Health Economics 1997; 6: 117-132.
53. Williams, M. Rationing health care. Can a 'fair innings' ever be fair? British Medical Journal 1997; 314: 514.
54. Brock, D.W. The role of ethics in the Clinton reform proposal. Journal of Health and Political Policy and Law 1994; 19: 217-220.
55. Brock, D.W. and Daniels, N. Ethical foundations of the Clinton administration's proposed health care system. Journal of the American Medical Association 1994; 271: 1189-1196.
56. Richardson, J. and Nord, E. The importance of perspective in the measurement of quality-adjusted life years. Medical Decision Making 1997; 17: 33-41.
57. Gold, M.R., Siegel, J.E., Russel, L.B. and Weinstein, M.C. (Eds) Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
58. Drummond, M., O'Brien, B.J., Stoddart, G.L. and Torrance, G. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1997.
59. Drummond, M.F., Bloom, B.S., Carrin, G. et al. Issues in the cross-national assessment of health technology. International Journal of Technology Assessment in Health Care 1992; 8: 671-682.
60. Leidl, R.M. Some factors to consider when using the results of economic evaluation studies at the population level. International Journal of Technology Assessment in Health Care 1994; 10: 467-478.
61. Birch, S. and Gafni, A. Cost-effectiveness ratios: in a league of their own. Health Policy 1994; 28: 133-141.
62. Drummond, M., Mason, J. and Torrance, G. Cost-effectiveness league tables: think of the fans. Health Policy 1995; 31: 231-238.
63. Glick, H., Willke, R., Polsky, D. et al. Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage: economic evaluation of a phase III clinical trial in Europe and Australia. International Journal of Technology Assessment in Health Care 1998; 14: 145-160.
64. Johnston, K., Gerard, K. and Brown, J. Generalizing costs from trials: analyzing center selection bias in a breast screening trial. International Journal of Technology Assessment in Health Care 1998; 14: 494-504.
65. Mason, J. The generalisability of pharmacoeconomic studies. PharmacoEconomics 1997; 11: 503-514.
66. Schulman, K., Burke, J., Drummond, M. et al. Resource costing for multinational neurologic clinical trials: methods and results. Health Economics 1998; 7: 629-638.
67. Willke, R.J., Glick, H., Polsky, D. et al. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Economics 1998; 7: 493.
68. Baltussen, R., Ament, A. and Leidl, R. Making cost assessments based on RCTs more useful to decision-makers. Health Policy 1996; 37: 163-183.
69. Commonwealth of Australia. Guidelines for pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including economic analyses. Canberra: Department of Health and Community Services, 1995.
70. Mitchell, A. Update and evaluation of Australian guidelines. Government perspective. Medical Care 1996; 34(Suppl): 216-225.
71. Langley, P.C. The November 1995 revised Australian guidelines for the economic evaluation of pharmaceuticals. PharmacoEconomics 1996; 9: 341-352.
72. Freund, D.A. Initial development of the Australian guidelines. Medical Care 1996; 34(Suppl): 211-215.
73. Aristides, M. and Mitchell, A. Applying the Australian guidelines for the reimbursement of pharmaceuticals. PharmacoEconomics 1994; 6: 196-201.
74. Gorham, P. Cost-effectiveness guidelines. The experience of Australian manufacturers. PharmacoEconomics 1995; 8: 369-373.
75. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for the economic evaluation of pharmaceuticals: Canada. Ottawa: CCOHTA, 1994.
76. Baladi, J.F., Menon, D. and Otten, N. Use of economic evaluation guidelines: 2 years' experience in Canada. Health Economics 1998; 7: 221-227.
77. Detsky, A.S. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. PharmacoEconomics 1993; 3: 354-361.
78. Glennie, J.L., Torrance, G., Baladi, J.F. et al. The revised Canadian guidelines for the economic evaluation of pharmaceuticals. PharmacoEconomics 1999; 15: 459-468.
79. Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Toronto: Ontario Ministry of Health, 1994.
80. Menon, D., Schubert, F. and Torrance, G.W. Canada's new guidelines for the economic evaluation of pharmaceuticals. Medical Care 1996; 34(Suppl): 77-86.
81. Torrance, G.W., Blaker, D., Detsky, A. et al. Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics. PharmacoEconomics 1996; 9: 535-559.
82. Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada. International Journal of Technology Assessment in Health Care 1995; 11: 796-797.
83. Lovatt, B. The United Kingdom guidelines for the economic evaluation of medicines. Medical Care 1996; 34(Suppl): 179-181.
84. Clemens, K., Townsend, R., Luscombe, F. et al. Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America. PharmacoEconomics 1995; 8: 169-174.
85. Ikeda, S., Ikegami, N., Oliver, A.J. et al. A case for the adoption of pharmacoeconomic guidelines in Japan. PharmacoEconomics 1996; 10: 546-551.
86. Alban, A., Gyldmark, M., Pedersen, A.V. et al. The Danish approach to standards for economic evaluation methodologies. PharmacoEconomics 1997; 12: 627-636.
87. Graf von der Schulenburg, J.M. Economic evaluation of medical technologies: from theory to practice - the German perspective. Social Science Medicine 1997; 45: 621-633.
88. Garattini, L., Grilli, R., Scopelliti, D. et al. A proposal for Italian guidelines in pharmacoeconomics The Mario Negri Institute Centre for Health Economics. PharmacoEconomics 1995; 7: 1-6.
89. Rovira, J. Standardizing economic appraisal of health technology in the European Community. Social Science Medicine 1994; 38: 1675-1678.
90. Rovira, J. Standardization of the economic evaluation of health technologies. European developments. Medical Care 1996; 34(Suppl): 182-188.
91. Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology. A report on principles. Annals of Internal Medicine 1995; 123: 61-70.
92. Bossert, W. Welfarism and rationalizability in allocation problems with indivisibilities. Mathematical Social Sciences 1998; 35: 133-150.
93. Kassirer, J.P. and Angell, M. The journal's policy on cost-effectivenss analysis. New England Journal of Medicine 1994; 331: 669-670.
94. Drummond, M.F. and Jefferson, T.O. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. British Medical Journal 1996; 313: 275-283.
95. Luce, B.R., Elixhauser, A., Culyer, A.J. and Horisberger, B. (Eds) Standards for socioeconomic evaluation of health care products and services. Berlin: Springer, 1990.
96. Rittenhouse, B.E. The standards debate. What have we learned? Medical Care 1996; 34(Suppl): 5-10.
97. Luce, B.R. and Simpson, K. Methods of cost-effectiveness analysis: areas of consensus and debate. Clinical Therapy 1995; 17: 109-125.
98. Freund, D.A. and Dittus, R.S. Principles of pharmacoeconomic analysis of drug therapy. PharmacoEconomics 1992; 1: 20-31.
99. Coyle, D. Statistical analysis in pharmacoeconomic studies. A review of current issues and standards. PharmacoEconomics 1996; 9: 506-516.
100. Schulman, K.A. and Linas, B.P. Pharmacoeconomics: state of the art in 1997. Annual Reviews in Public Health 1997; 18: 529-548.
101. Blackmore, C.C. and Smith, W.J. Economic analyses of radiological procedures: a methodological evaluation of the medical literature. European Journal of Radiology 1998; 27: 123-130.
102. Blackmore, C.C. and Magid, D.J. Methodologic evaluation of the radiology cost-effectiveness literature. Radiology 1997; 203: 87-91.
103. Hayman, J., Weeks, J. and Mauch P. Economic analyses in health care: an introduction to the methodology with an emphasis on radiation therapy. International Journal of Radiation in Oncology and Biological Physics 1996; 35: 827-841.
104. Talley, C.R. Pharmacoeconomic principles. American Journal of Health Systems and Pharmaceutics 1995; 52: 1871.
105. Luce, B.R. Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals. PharmacoEconomics 1993; 3: 1-9.
106. Lafata, J.E., Koch, G.G. and Ward, R.E. Synthesizing evidence from multiple studies. The role of meta-analysis in pharmacoeconomics. Medical Care 1996; 34(Suppl): 136-145.
107. Jolicoeur, L.M., Jones-Grizzle, A.J. and Boyer, J.G. Guidelines for performing a pharmacoeco-nomic analysis. American Journal of Hospitals and Pharmacy 1992; 49: 1741-1747.
108. Rittenhouse, B.E. Is there a need for standardization of methods in economic evaluations of medicine? Medical Care 1996; 34(Suppl): 13-22.
109. Gafni, A. and Birch, S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. Canadian Medical Association Journal 1993; 148: 913-917.
110. Sacristan, J.A., Soto, J. and Galende, I. Evaluation of pharmacoeconomic studies: utilization of a checklist. Annals of Pharmaco therapy 1993; 27: 1126-1133.
111. Lee, J.T. and Sanchez, L.A. Interpretation of 'cost-effective' and soundness of economic evaluations in the pharmacy literature. American Journal of Hospitals and Pharmacy 1991; 48: 2622-2627.
112. Henry, D. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals. PharmacoEconomics 1992; 1: 54-67.
113. Johannesson, M. and O'Brien, B.J. Economics, pharmaceuticals, and pharmacoeconomics. Medical Decision Making 1998; 18(Suppl): 1-3.
114. Luce, B.R. Working toward a common currency: is standardization of cost-effectiveness analysis possible? Journal of Acquired Immune Deficiency Syndrome Human Retrovirology 1995; 10: 19-22.
115. Siegel, J.E., Torrance, G.W., Russell, L.B. et al. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. PharmacoEconomics 1997; 11: 159-168.
116. Drummond, M.F. Guidelines for pharmacoeconomic studies. The ways forward. PharmacoEconomics 1994; 6: 493-497.
117. Drummond, M.F. A reappraisal of economic evaluation of pharmaceuticals. Science or marketing? PharmacoEconomics 1998; 14: 1-9.
118. Jacobs, P., Bachynsky, J. and Baladi, J.F. A comparative review of pharmacoeconomic guidelines. PharmacoEconomics 1995; 8: 182-189.
119. Mason, J. and Drummond, M. Reporting guidelines for economic studies. Health Economics 1995; 4: 85-94.
120. Drummond, M. and Mooney, G. Economic appraisal in health care: 1. A guide to the methodology of economic appraisal. Hospital Health Services Review 1981; 77: 277-282.
121. Drummond, M. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Economics 1992; 1: 85-92.
122. Drummond, M.F. and Davies, L. Economic analysis alongside clinical trials. Revisiting the methodological issues. International Journal of Technology Assessment in Health Care 1991; 7: 561-573.
123. Drummond, M.F., Richardson, W.S., O'Brien, B.J. et al. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group. Journal of the American Medical Association 1997; 277: 1552-1557.
124. Manning, W.G.J. Panel on cost-effectiveness in health and medicine recommendations: identifying costs. Journal of Clinical Psychiatry 1999; 60(Suppl 3): 54-56.
125. Brouwer, W.B.F., Koopmanschap, M.A. and Rutten, F.F.H. Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel. Health Economics 1997; 6: 253-259.
126. Cantor, S.B. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Medical Decision Making 1994; 14: 259-265.
127. Cantor, S.B. and Ganiats, T.G. Incremental cost-effectiveness analysis: the optimal strategy depends on the strategy set. Journal of Clinical Epidemiology 1999; 52: 517-522.
128. Garber, A.M. Advances in cost-effectiveness analysis of health interventions. Working Paper 7198, NBER Working Paper Series, 1999.
129. Ament, A. and Baltussen, R. The interpretation of results of economic evaluation: explicating the value of health. Health Economics 1997; 6: 625-635.
130. Weinstein, MC. From cost-effectiveness ratios to resource allocation: where to draw the line? In: Sloan, F. (Ed.), Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. New York: Cambridge University Press, 1996, pp. 77-97.
131. Johannesson, M. and Meltzer, D. Some reflections on cost-effectiveness analysis. Health Economics 1998; 7: 1-7.
132. Laska, E.M., Meisner, M. and Siegel, C. The usefulness of average cost-effective ratios. Health Economics 1997; 6: 504.
133. Laska, E.M., Meisner, M., Siegel, C. et al. Ratio-based and net benefit-based approaches to health care resource allocation: proofs of optimaltiy and equivalence. Health Economics 1999; 8: 174.
134. Craven, P.C. Treating bone and joint infections with teicoplanin: hospitalization vs outpatient cost issues. Hospital Formula 1993; 28(Suppl): 41-45.
135. Tubman, T.R., Halliday, H.L. and Normand, C. Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial [published erratum appears in BMJ 1991 Jan 5; 302(6767): 27]. British Medical Journal 1990; 301: 842-845.
136. Fendrick, A.M., Lee, J.H., LaBarge, C. et al. Clinical and economic impact of a combination Haemophilus influenzae and Hepatitis B vaccine: estimating cost-effectiveness using decision analysis. Archives of Pediatrics and Adolescence Medicine 1999; 153: 126-136.
137. Goldie, S.J., Kuntz, K.M., Weinstein, M.C. et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. Journal of the American Medical Association 1999; 281: 1822-1829.
138. Krahn, M., Guasparini, R., Sherman, M. et al. Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. American Journal of Public Health 1998; 88: 1638-1644.
139. O'Brien, B.J., Goeree, R., Hux, M. et al. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. Journal of the American Geriatric Society 1999; 47: 570-578.
140. Murray, CJ. Rethinking DALYs. In: Murray, C.J. and Lopez, A.D. (Eds), The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University Press, 1996, pp. 1-98.
141. Davis, G.L., Beck, J.R., Farrell, G. et al. Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis. Journal of Viral Hepatitis 1998; 5: 313-321.
142. Murray, C.J., DeJonghe, E., Chum, H.J. et al. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 1991; 338: 1305-1308.
143. Molineaux, L., Storey, J., Cohen, J.E. et al. A longitudinal study of human malaria in the West African Savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene 1980; 29: 725-737.
144. Struchiner, C.J., Halloran, M.E. and Spielman, A. Modeling malaria vaccines. I: New uses for old ideas. Mathematics and Biosciences 1989; 94: 87-113.
145. Koella, J.C. On the use of mathematical models of malaria transmission. Acta Tropica 1991; 49: 1-25.
146. Joesoef, M.R., Remington, P.L. and Jiptoherijanto, P.T. Epidemiological model and cost-effectiveness analysis of tuberculosis treatment programmes in Indonesia. International Journal of Epidemiology 1989; 18: 174-179.
147. Kuo, H.S., Chang, H.J., Chou, P. et al. A Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM). International Journal of Epidemiology 1999; 28: 233-240.
148. Samsa, G.P., Reutter, R.A., Parmigiani, G. et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. Journal of Clinical Epidemiology 1999; 52: 259-271.
149. Van-Damme, P., Tormans, G., Beutels, P. et al. Hepatitis B prevention in Europe: a preliminary economic evaluation. Vaccine 1995; 13(Suppl): 54-57.
150. de-Koning, H.J., van-Ineveld, B.M., van-Oortmarssen, G.J. et al. Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. International Journal of Cancer 1991; 49: 531-537.
151. de-Koning, H.J., van-Ineveld, B.M., de-Haes, J.C. et al. Advanced breast cancer and its prevention by screening. British Journal of Cancer 1992; 65: 950-955.
152. Jönsson, B. and Weinstein, M.C. Economic evaluation alongside multinational clinical trials: study considerations for GUSTO IIb. International Journal of Technology Assessment in Health Care 1997; 13: 49-58.
153. Van der Werf, F., Topol, E.J. and Lee, K.L. Variations in patients management and outcomes for acute myocardial infarction in the United States and other countries: results from the GUSTO trial. Journal of the American Medical Association 1995; 273: 1586-1591.